Login to Your Account

'MiR'-anda right in HCV? Regulus offers proof in early phase I, Wall Street's conviction high

By Randy Osborne
Staff Writer

Wednesday, October 22, 2014

Making good on preclinical whispers heard at last year's American Association for the Study of Liver Diseases meeting, Regulus Therapeutics Inc. disclosed interim phase I proof-of-concept data showing that one subcutaneous 2 mg/kg dose of its HCV candidate RG-101 knocked down HCV RNA in a diverse group of patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription